Compare Indonesia Energy Corporation Limited (INDO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Moderna, Inc. — how do they compare? Indonesia Energy Corporation Limited trades at $2.9 (market cap $45.55M), while Moderna, Inc. trades at $62.21 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 530.8× Indonesia Energy Corporation Limited's market cap, and Moderna, Inc. is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| INDO | MRNA | |
|---|---|---|
Market Cap | $45.55M | $24.18B |
Sector | Energy | Health |
52-Week High | $6.74 | $81.80 |
52-Week Low | $2.49 | $22.36 |
Enterprise Value | $40.92M | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Indonesia Energy Corporation (INDO) trades at $2.89, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company is actively drilling the K-29 well at its Kruh Block, indicating operational progress. Financially, it shows deep losses with a net income margin of -253.4% and negative ROE of -26.95% for 2025, though it beat EPS estimates in Q2 2025. Valuation metrics include a P/S of 21.57 and P/B of 2.32, reflecting high sales multiples amid profitability challenges.
The outlook hinges on successful well outcomes driving future revenue; current analyst consensus is 100% buy, but high execution risks and persistent losses pose significant threats to shareholder value. Investors face volatility from oil price swings and operational delays.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
